Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine . Phase 2 results from LILAC and AMETHYST supported litifilimab's recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology. Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment

BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of the certification of a class action on behalf of purchasers of BioGen, Inc. securities (NASDAQ: BIIB):

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaking data from Part A (Phase 2) of the AMETHYST Phase 2/3 study will be presented that highlight litifilimab's effect on cutaneous lupus erythematosus (CLE) disease activity. Litifilimab is a potential first in-class, monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and was the first investigational therapy to show positive results in CLE, as shown in the Phase 2 LILAC study. Additional presentations at AAD will provide new insights into measures used to assess the severity of CLE disease activity in both clinical trials and clinical practice.

Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript